UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2021
| INMUNE BIO INC. | ||
| (Exact name of registrant as specified in charter) |
| Nevada | 001-38793 | 47-5205835 | ||
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
1200 Prospect Street, Suite 525, La Jolla, CA 92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per shares | INMB | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On April 26, 2021, INmune Bio Inc., a Nevada corporation (the “Company”), issued a press release announcing that Raymond J.
Tesi, MD will participate in a fireside chat at the B Riley Neuroscience Conference on Wednesday, April 28, 2021. A copy of this press
release is attached as Exhibit 99.1
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
|
Exhibit
Number |
Description | |
| 99.1 | Press Release dated April 26, 2021 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| Date: April 27, 2021 | By: | /s/ David Moss |
| David Moss | ||
| Chief Financial Officer | ||
3
Exhibit 99.1
INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference
LA JOLLA, Calif, April 23, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will participate in a fireside chat at the B Riley Neuroscience Conference on Wednesday, April 28.
B Riley Neurosciences Conference
Fireside Chat Date: Wednesday, April 28, 2021
Presentation Time: 1:00 PM Eastern Time
Webcast: https://www.webcaster4.com/Webcast/Page/2433/41046
Please contact your representative at B Riley to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target
the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative
technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF
is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH
(LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate
minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment
of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Information about Forward-Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in
this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may
constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and
the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials
or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that
any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials;
the availability of substantial additional funding for the Company to continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval,
marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s
filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
Chuck Padala
LifeSci Advisors, LLC
(917) 741-7792
Chuck@lifesciadvisors.com